Overview

  • Product name
    Anti-TACI antibody (Biotin)
    See all TACI primary antibodies
  • Description
    Goat polyclonal to TACI (Biotin)
  • Conjugation
    Biotin
  • Tested applications
    Suitable for: ELISA, Sandwich ELISA, WB, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Highly pure (>98%) recombinant human TACI

  • General notes
    ab83515 is sterile filtered.

Properties

  • Form
    Lyophilised:Centrifuge vial prior to opening. Reconstitute in sterile PBS containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: None
    Constituents: PBS, pH 7.2
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab83515 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
Sandwich ELISA
WB
IP
  • Application notes
    ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human TACI.
    sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human TACI.
    WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human TACI is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 32 kDa.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
    • Tissue specificity
      Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
    • Involvement in disease
      Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
      Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
    • Sequence similarities
      Contains 2 TNFR-Cys repeats.
    • Cellular localization
      Membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD 267 antibody
      • CD267 antibody
      • CD267 antigen antibody
      • CVID antibody
      • CVID2 antibody
      • FLJ39942 antibody
      • MGC133214 antibody
      • MGC39952 antibody
      • OTTHUMP00000065442 antibody
      • TNFRSF 13B antibody
      • TNFRSF 14B antibody
      • TNFRSF13B antibody
      • TNFRSF13B protein antibody
      • TNFRSF14B antibody
      • TR13B_HUMAN antibody
      • Transmembrane activator and CAML interactor antibody
      • Tumor necrosis factor receptor 13B antibody
      • Tumor necrosis factor receptor superfamily member 13B antibody
      see all

    References for Anti-TACI antibody (Biotin) (ab83515)

    This product has been referenced in:
    • Romberg N  et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest 123:4283-93 (2013). IP ; Human . Read more (PubMed: 24051380) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab83515.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up